Many thousands ofchemicals are produced industrially and many more occur naturally. Information on the toxicology of these chemicals is often minimal or absent. The International Agency for Research on Cancer (IARC) has published evaluations ofthe carcinogenic risk to humans ofover 700 chemica4 groups ofchemicals, andcompex mixtures as a regular series of monographs. A database has been created containingsummanies ofall the relevant epidemiological, animal carcinogenicity, and other relevant biological data for each chemical or mixture evaluated. Additional databases have been created for ongoing epidemiological studies ofcancer in humans and for long-term carcinogenicity studies in rodents, as well as a database contalning information on genotoxic and related effects ofchemicals. Some ofthese databases have been published in print form. IARC now plans to publish them electronically, together with other databases, in the form of a CDROM (compact disk, read-only memory). The objective will be to make the entire IARC database ofcancer information as widely available as possible in an integrated format conducive to efficient and combined exploitation of all the component databases.
Introduction: Chemicals, Carcinogens, and Hazards to Humans
Estimates vary as to the number ofchemicals that are produced in significant amounts. In 1980, the European Core Inventory (ECDIN) listed about 34,000 chemical substances believed to be on the European Community market (1) . Later, Shulze and Mucke (2) estimated that there were about 100,000 chemicals on the market within the European Community. Recently, it has been estimated on the basis of the U.S. Toxic Substance Control Act inventory that people in the United States are exposed to about 66,000 chemical substances (3) , and some 300 to 700 new industrial chemicals are introduced annually into economnic use (4) . The fact that even minimal toxicity data are available for only a minority of these chemicals is due to the rapid development of new industrial activities during a period in which health problems related to chemicals received little attention. Several thousand chemicals on the market have been tested to some extent for carcinogenicity in long-term animal studies; however, the number of chemicals tested adequately and for which there are publications in the open literature is much lower. It should be noted that a small proportion of all the chemicals accounts for most of the production: for instance, 380 primary derivatives of petroleum products account for more than halfofthe production tonnage of all chemicals (5) .
The International Agency for Research on Cancer (IARC) has been involved in preparing and disseminating scientific information relevant to cancer control for more than 25 years. During this period, extensive collections of data on carcinogenicity and related effects of chemicals and specific exposures have been made available to the scientific community as a series ofover 50 volumes ofIARCMonographs on the Evaluation ofCarcinogenic Risks to Humans (6) . During the preparation and periodical updating of these carcinogenicity evaluations, several ancillary databases have been developed and maintained alongside the IARC Monographs themselves, mainly for internal use. In this briefreview, we describe the nature and content ofthese databases and discuss some ofthe perspectives for their future development. 4 , the agent, mixture or exposure circumstance is probably not carcinogenic to humans (there is evidence suggesting lack of carcinogenicity in humans together with evidence suggesting lack ofcarcinogenicity in experimental animals; in some instances, an agent for which there is inadequate evidence or no data on carcinogenicity in humans but evidence suggesting lack of carcinogenicity in experimental animals, consistently and strongly supported by a broad range of other relevant data, may be placed in this category). Table 1 gives the distribution of all the agents evaluated up to 1990 (IARC Monographs volumes 1-53) into these five categories.
The categorizations given in Table 1 are clearly related to exposure and not to a specific target organ. This is because the primary goal of the IARC Monographs program is to reach an evaluation ofcarcinogenicity per se, and the working procedures used do not embody provision to classify exposures as to their carcinogenicity for specified target organs. However, for an agent to be classified in group 1, there must be at least one target organ for which sufficient evidence of carcinogenicity in humans is judged to exist (Table 2) . Similarly, for all agents judged to have aThe evaluations in the IARC Monographs are qualitative, reflecting the strength ofthe evidence as to the carcinogenicity ofthe agent concerned derived from studies in humans and in experimental animals and from other relevant data. This means that the assessment is of the strength of evidence as to whether a substance is carcinogenic, not as to the degree, ifany, to which it is carcinogenic. bCriteria for selection of agents evaluated in the IARC Monographs is based mainly on a suspicion ofcarcinogenicity as published in the scientific literature.
sufficient evidence of carcinogenicity in experimental animals, the judgment is usually based on evidence from one or more species. Target organs may differ from one species to another for many exposures causally related to human cancers; however, there is almost always at least one organ in common between humans and at least one animal species, despite many inherent physiological differences between species (7).
IARC Monographs Compound Database
A computerized database has been created for all chemicals, groups ofchemicals, complex mixtures, or exposures evaluated in volumes 1-53 of the IARC Monographs. For each agent, the database contains the Chemical Abstracts Service Registry Number (CAS number), the chemical name, monographs reference (volume, year, page) and supplement 7 reference (page). In addition, the following data are presented in indexed format and can be searched using boolean logic: a) overall evaluation ofcarcinogenicity to humans; b) degree ofevidence of carcinogenicity in humans and in animals (according to the criteria given in the Preamble to the IARC Monographs); c) chemical class-main molecular structural group(s); d) use class-main industrial use or exposure circumstance; e) for each report/experiment considered in the evaluation, the species, route of exposure, target organ, certainty (degree of evidence evaluation for the organ concerned), tumor type and bibliographical citation; J) short-term test and related data: phylogenetic level, genetic and related end point, result; and g) teratogenicity, embryotoxicity, and fetotoxicity data.
LARC/EPA Genetic Activity Profiles
The data used in the IARCMonographs on genetic and related effects have been prepared together with the U.S. Environmental Protection Agency (EPA) in the form ofgenetic activity profiles (8, 9) The combined utility ofthe information in the IARC databases described here may be even wider than appears from a consideration of each database alone. The whole may be greater than the sum of the parts.
The optimal exploitation of this large body of information, however, would require creation ofa single electronic database containing all the individual databases. It should now be possible to integrate all this material into a single, comprehensive and readily accessible set ofauthoritative information on published experimental and human studies, with expert evaluations of carcinogenicity to humans (the IARC Monographs and ancillary databases), together with up-to-date listings of all current research in animals (Directory ofAgents Being Testedfor Carcinogenicity) and in humans (Directory ofOn-Going Research in Cancer Epidemiology). Such an information resource could, for example, be used to streamline the review and evaluation of current knowledge and to help identify the most effective research strategies to extend this knowledge.
Many other uses could be described for such an integrated data set, but the ability to disseminate the entire IARC database of cancer research information to a much wider audience than is currently possible, particularly in developing countries, could be a major additional advantage ofmanaging the data in this way. It could also permit regular updating and correction.
This possibility is under active consideration. It will require development ofthe data in two broad domains. First, the existng databases will need to become structurally aligned: although they are conceptually coherent, they have been developed in different ways for conventional publication in print and are structurally diverse. Second, this conceptual coherence will need to be reflected in a search and retrieval program that enables the full range of information to be exploited without the need for computing skills. Finally, it will be necessary to make this material available in a widely accessible format at an affordable cost.
Initial Experiments
Initial steps in partial electronic publication of two of the databases have already been made: the Directory ofOn-Going Research in Cancer Epidemiology and the genetic activity profiles ofcompounds evaluated in the IARCMonographs program. Seven of the eight indexes of the 1989/90 and 1991 directories were published on a single IBM-compatible diskette and distributed with every copy ofthe printed DirectoryofOn-Going Research (11, 13 
Electronic Options
There are several ways in which the information described here could be made available in electronic form. These include diskettes, on-line systems, and CDROM (compact disk, readonly memory).
Use ofdiskettes to distribute the indexes, as for the Directory ofOn-Going Research, enables more powerful searching than is possible with print publication, but it has several drawbacks. To examine the result of a search, the user must have all the printed texts available and cannot review or refine the results ofa search before examining the original source documents. In addition, a large number ofdiskettes would be required, which complicates the task ofdistribution, computer storage and regular updating.
Making the databases available on existing on-line information retrieval systems such as MEDLINE (U.S. National Library of Medicine) or EUROCODE (European Organization for Research and Treatment ofCancer) or creating a new on-line host system is another possibility. It would solve the problems of database size and of updating the database and the search software because all these aspects would be managed at the on-line source, requiring no action by the user. From the viewpoint of the IARC, however, this option has three drawbacks. First, and most important, on-line systems are typically available only in developed countries with the appropriate telecommunications infrastructure. Second, on-line access is expensive, as the cost relates to time used on the host mainframe computer and on the telecommunications system used to establish contact with it, rather than to the information supplied. Third, access is sometimes difficult because ofproblems in telecommunications, such as long waiting times during peak periods and incompatibility of various communications interfaces.
The preferred solution would appear to be CDROM: this is the least expensive mass data storage medium developed so far. A 12-cm diameter disk can hold 650 megabytes of data, which is the equivalent of 250 books or 1500 floppy diskettes. CDROM readers are inexpensive and widely available and can be attached to most personal computers by a standard connection. Software for rapid search of large text databases on CDROM is also available. CDROM disks conform to a widely accepted international standard (ISO-9660 or the High Sierra Standard) for information exchange, which means that problems of compatibility between disks and CDROM readers are unlikely. Finally, provision ofall the text, indexes, and software on a single CDROM, for use with personal computer technology, which is widely available even in developing countries, represents an attractive way ofmaking the information available to the widest possible audience. It is likely that purchase ofthe CDROM and hardware needed to use it would cost less than the purchase and despatch of all the books involved (some of which are out of print).
